Nuclear and membrane expression of the angiogenesis regulator delta-like ligand 4 (DLL4) in normal and malignant human tissues - PubMed (original) (raw)
Nuclear and membrane expression of the angiogenesis regulator delta-like ligand 4 (DLL4) in normal and malignant human tissues
Juan Carlos Martinez et al. Histopathology. 2009 Apr.
Retraction in
- Corrigendum.
Turley H, Steers G, Li JL, Sainson R, Harris AL, Pezzella F, Gatter KC. Turley H, et al. Histopathology. 2009 Oct;55(4):463-4. doi: 10.1111/j.1365-2559.2009.03412.x. Histopathology. 2009. PMID: 19817897 No abstract available.
Abstract
Aims: Delta-like ligand 4 (DLL4) is one of five known Notch ligands in mammals and interacts predominantly with Notch 1. DLL4 is induced by vascular endothelial growth factor (VEGF) and acts downstream of VEGF as a 'brake' on VEGF-induced vessel growth, forming an autoregulatory negative feedback loop inactivating VEGF. This action was believed to occur only in vascular development, raising hopes that DLL4 could be a specific drug target for controlling vessel growth in tumours and other pathological conditions. Our aim was to pursue this by raising a monoclonal antibody to the internal domain of DLL4 and assess its distribution in normal and malignant tissues in comparison with antibodies against the external domain of DLL4.
Methods and results: The anti-DLL4 monoclonal antibody was raised using conventional mouse hybridoma techniques. The antibody has been fully characterized by Western blotting and transfectant immunostaining. It has also been comprehensively compared with other antibodies against both the internal and external domains of DLL4. The antigen is widely expressed on human tissues not only on endothelium but also on epithelium and stromal cells. Indeed, in our comprehensive survey only pulmonary alveoli failed to express DLL4. Of a wide range of malignancies, most also expressed DLL4 on tumour cells with a predominantly cytoplasmic pattern, although a number also displayed nuclear positivity.
Conclusions: Contrary to previous beliefs, DLL4 is widely distributed in tissues other than vessels including many malignancies. Furthermore, the molecule is internalized on binding its receptor and often transported to the nucleus. These findings raise many interesting possibilities for further study of DLL4 and its potential as a therapeutic target.
Similar articles
- Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function.
Patel NS, Li JL, Generali D, Poulsom R, Cranston DW, Harris AL. Patel NS, et al. Cancer Res. 2005 Oct 1;65(19):8690-7. doi: 10.1158/0008-5472.CAN-05-1208. Cancer Res. 2005. PMID: 16204037 - Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer.
Patel NS, Dobbie MS, Rochester M, Steers G, Poulsom R, Le Monnier K, Cranston DW, Li JL, Harris AL. Patel NS, et al. Clin Cancer Res. 2006 Aug 15;12(16):4836-44. doi: 10.1158/1078-0432.CCR-06-0285. Clin Cancer Res. 2006. PMID: 16914569 - Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo.
Li JL, Sainson RC, Shi W, Leek R, Harrington LS, Preusser M, Biswas S, Turley H, Heikamp E, Hainfellner JA, Harris AL. Li JL, et al. Cancer Res. 2007 Dec 1;67(23):11244-53. doi: 10.1158/0008-5472.CAN-07-0969. Cancer Res. 2007. PMID: 18056450 - Delta-like 4/Notch signaling and its therapeutic implications.
Yan M, Plowman GD. Yan M, et al. Clin Cancer Res. 2007 Dec 15;13(24):7243-6. doi: 10.1158/1078-0432.CCR-07-1393. Clin Cancer Res. 2007. PMID: 18094402 Review. - New pathways and mechanisms regulating and responding to Delta-like ligand 4-Notch signalling in tumour angiogenesis.
Oon CE, Harris AL. Oon CE, et al. Biochem Soc Trans. 2011 Dec;39(6):1612-8. doi: 10.1042/BST20110721. Biochem Soc Trans. 2011. PMID: 22103496 Review.
Cited by
- Endothelial Dll4 overexpression reduces vascular response and inhibits tumor growth and metastasization in vivo.
Trindade A, Djokovic D, Gigante J, Mendonça L, Duarte A. Trindade A, et al. BMC Cancer. 2017 Mar 14;17(1):189. doi: 10.1186/s12885-017-3171-2. BMC Cancer. 2017. PMID: 28288569 Free PMC article. - Myeloid DLL4 Does Not Contribute to the Pathogenesis of Non-Alcoholic Steatohepatitis in Ldlr-/- Mice.
Jeurissen ML, Walenbergh SM, Houben T, Hendrikx T, Li J, Oligschlaeger Y, van Gorp PJ, Gijbels MJ, Bitorina A, Nessel I, Radtke F, Vooijs M, Theys J, Shiri-Sverdlov R. Jeurissen ML, et al. PLoS One. 2016 Nov 29;11(11):e0167199. doi: 10.1371/journal.pone.0167199. eCollection 2016. PLoS One. 2016. PMID: 27898698 Free PMC article. - The Notch ligand DLL4 specifically marks human hematoendothelial progenitors and regulates their hematopoietic fate.
Ayllón V, Bueno C, Ramos-Mejía V, Navarro-Montero O, Prieto C, Real PJ, Romero T, García-León MJ, Toribio ML, Bigas A, Menendez P. Ayllón V, et al. Leukemia. 2015 Aug;29(8):1741-53. doi: 10.1038/leu.2015.74. Epub 2015 Mar 17. Leukemia. 2015. PMID: 25778099 - The role of notch in the cardiovascular system: potential adverse effects of investigational notch inhibitors.
Rizzo P, Mele D, Caliceti C, Pannella M, Fortini C, Clementz AG, Morelli MB, Aquila G, Ameri P, Ferrari R. Rizzo P, et al. Front Oncol. 2015 Jan 13;4:384. doi: 10.3389/fonc.2014.00384. eCollection 2014. Front Oncol. 2015. PMID: 25629006 Free PMC article. Review. - Identification of putative ortholog gene blocks involved in gestant and lactating mammary gland development: a rodent cross-species microarray transcriptomics approach.
Rodríguez-Cruz M, Coral-Vázquez RM, Hernández-Stengele G, Sánchez R, Salazar E, Sanchez-Muñoz F, Encarnación-Guevara S, Ramírez-Salcedo J. Rodríguez-Cruz M, et al. Int J Genomics. 2013;2013:624681. doi: 10.1155/2013/624681. Epub 2013 Oct 30. Int J Genomics. 2013. PMID: 24288657 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources